Retatrutide is a synthetic peptide, which research indicates functions as a triple agonist for type 2 diabetes and weight loss. Peptides, small chains of amino acids, have been hypothesized to ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Retatrutide is an new drug that has shown promise in the treatment of obesity and type 2 diabetes. Retatrutide is a type of multi-receptor agonist that targets multiple hormonal pathways involved in ...

Retatrutide Peptide Retatrutide is a synthetic peptide designed to mimic the activity of naturally occurring hormones in the organism. Its structure comprises a sequence of amino acids that ...